Guided Therapeutics Inc. (OTCMKTS:GTHP) Sees Significant Decline in Short Interest

Guided Therapeutics Inc. (OTCMKTS:GTHP) was the recipient of a large decline in short interest in the month of September. As of September 30th, there was short interest totaling 3,727 shares, a decline of 45.4% from the September 15th total of 6,822 shares. Based on an average daily trading volume, of 127,857 shares, the short-interest ratio is currently 0.0 days. Approximately 0.0% of the company’s stock are short sold.

Guided Therapeutics Stock Performance

OTCMKTS:GTHP remained flat at $0.19 on Friday. 110 shares of the company’s stock were exchanged, compared to its average volume of 45,653. The stock’s 50-day moving average price is $0.23 and its 200-day moving average price is $0.23. The company has a market cap of $18.66 million, a PE ratio of -4.75 and a beta of 0.70. Guided Therapeutics has a one year low of $0.15 and a one year high of $0.54.

Guided Therapeutics (OTCMKTS:GTHP) last announced its earnings results on Thursday, August 13th. The company reported ($0.01) earnings per share (EPS) for the quarter.

Guided Therapeutics Company Profile

Guided Therapeutics, Inc is a medical technology company focused on developing diagnostic products for women’s health. The company’s primary focus has been the detection of cervical disease and cancer using minimally invasive or non-invasive technologies.

Its lead product, LuViva Advanced Cervical Scan, is designed to evaluate cervical tissue using optical spectroscopy. The system analyzes changes in tissue characteristics that may be associated with precancerous or cancerous conditions and is intended to help clinicians identify patients who may require additional evaluation, including biopsy.

Guided Therapeutics has pursued regulatory and commercial opportunities for its cervical disease detection technology in the United States and international markets.